The first long-term trial of peanut allergy immunotherapy results are positive

Peanut allergy sufferers are the most common food allergies, and severe allergic reactions can be life-threateningIn general, the prevention of peanut allergies is to avoid contact with peanut products, however, because the ingredients of peanuts may appear in unexpected foods, and for allergy patients, a small amount of peanut protein can trigger severe allergic reactionsThis unpredictable risk hangs over them like the Sword of Damox, affecting the quality of life of patients and the daily lives of family membersPalforzia is the FDA-approved first food allergy treatment, which works by giving peanut allergy patients a small amount of peanut protein, allowing the patient's immune system to desensitis peanut proteinIn A Phase 3 clinical trial called PALISADE, 67.2% of patients treated with Palforzia were able to tolerate a 600 mg dose of peanut protein at the end of a 52-week course of treatmentIn the placebo-controlled group, the figure was only 4.0%However, because this treatment is actually treated with allergens that cause allergies in patients, some patients may also have side effects of peanut allergies during treatmentAlthough the treatment was approved by the FDA in January, doubts remain about the long-term safety of the treatment and whether it will improve the quality of life of patientspatients who were able to tolerate a 300 mg dose of peanut protein were added to a development label extension trial called ARC004 after PALISADE was completedThey continued to receive Palforzia at a dose of 300 mg/day for 28 weeks (n?103) and 56 weeks (n-26)THE results of the ARC004 trial showed that 80.8 percent of patients who continued to receive 56 weeks of treatment were able to tolerate 2000 mg of peanut protein (equal to 12 peanuts) at the end of the courseFor patients who received treatment for 28 weeks, the figure was 49%This means that as the duration of treatment increases, the patient's desensitization level is also increasedAlso, patients experienced 59 percent (28 weeks) and 85 percent (56 weeks) of side effects, respectivelyin addition,assessment of patient sequality showed a significant improvement in the quality of life index of patients treated with Palforzia in the ARC004 trialThis means that long-term use of Palforzia can lead to clinically significant improvements in the emotional and social effects of peanut allergies, such as anxiety and stress due to concerns about peanut allergic reactions "We are pleased to be able to share long-term data from Palforzia, which shows that patients who continue to receive treatment have an increased immune system to increase their tolerance to allergens," said Dr Daniel Adelman, Chief Medical Officer of Aimmune "
References: .™ Retrieved March 14, 2020, from http://ir.aimmune.com/news-releases/news-release-details/aimmune-announces-new-palforziatm-data-suggesting-increased original title: Express - Gospel for Peanut Allergy Patients, First Immunotherapy Long-Term Trial Results Positive